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Editor’s note: 52 pages might
seem like a lot, but even that
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of Women in Medicine Website,”
and can be found here: medicine.
yale.edu/centuryofwomen.
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dialogue

		 The bottom-up revolution driving
microbiome research at Yale
f u e l e d by t ec h nol o gic a l br e a k t h rough s and a wealth
of information gleaned from private research and government-funded
programs, lines of inquiry into human and non-human microbiomes
have proliferated in recent years. Robert J. Alpern, MD, dean and Ensign
Professor of Medicine, describes the field’s blossoming significance, and
how YSM has fostered research in New Haven.
How have attitudes toward the microbiome evolved during your professional career? While
in the past, there were interesting observations about the potential importance of the
microbiome, today, the microbiome is one of the more exciting frontiers of medicine.
While it hasn’t fully defined itself in terms of its importance to homeostasis, or how
useful it will be in preventing and treating disease, there’s accumulating evidence that
it will be very important to both. “Health” as we think of it may actually be the result
of an interplay between our individual genome and the composition of our microbiome
and the effects of both on our homeostatic processes, so it’s a vital area of research.
What has the School of Medicine done to prepare for increased activity with the microbiome?

First, we’ve recruited outstanding scientists. Second, we’ve built facilities to support
those scientists. We’ve staked out a leadership position in this field and ensured that we
have a framework to capitalize on what appears to be a likely upcoming boom of investigators (and investigations) into the microbiome. From the standpoint of the school, we
want to establish core facilities that allow any researcher, no matter their area of interest, the ability to work with the microbiome.
Was that by design? Yes and no. A number of departments decided to recruit in this area.
We agreed to build facilities to support their efforts. I think this is a typical bottom-up
success story where departments decided the scientific priorities, the areas they think
Yale needed to investigate, and YSM supported those priorities. Then, once the right
people were here, and the facilities came online, other people who weren’t necessarily
working in the area chose to expand their research.
How has this affected the field of nephrology? The kidney is significantly affected by
immunologic diseases, a class of disease that has seen significant correlative overlap with microbiome research. One disease that affects the kidney, IgA nephropathy,
involves an antibody that occurs in mucosal interfaces. I wouldn’t be surprised if it
turns out that IgA nephropathy was influenced by the microbiome. It’s exciting to
be a doctor or researcher at Yale today, with all these longstanding mysteries being
resolved—and new questions posed for future scientists!
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			 Yale and the VA:
		 Joined at the hip
on the first day of her residency rotation at the va
hospital in West Haven, Susan Kashaf, MD, MPH, treated
Kevin Barbour, a Vietnam War veteran. Barbour was
exasperated by lingering pain from earlier knee surgery—
and he let her know about it.
It was a rough start for a young
doctor. “He scared the heck out
of me,” recalls Kashaf.
Today, 20 years later, Kashaf
is an attending physician at the
VA and an associate professor
of medicine at Yale School of
Medicine—and Barbour is still

one of her patients. She has a
thank-you card that he sent her
after she helped him quit smoking. “It’s a nice reminder of what
we do,” says Kashaf.
Barbour says he rarely sends
thank-you notes, but, he felt
compelled to reach out to Kashaf.

Many doctors at Yale,
including Susan Kashaf,
right, and hospital
resident Mary Barden,
treat veterans at the VA
Connecticut Healthcare
System’s West Haven
facility. Kashaf has been
providing service at the
VA since her residency
20 years ago, and has developed lasting relationships with her patients.

Caption
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“She has been my primary care
doctor for 20 years. It’s nice to
know that somebody is watching over me,” he says.
The warm feelings shared
by Kashaf and Barbour are
emblematic of the deep and
multifaceted relationship
between Yale School of Medicine
and the VA Connecticut
Healthcare System in West
Haven that goes back more than
60 years. People involved say the
tie is critically important to the
delivery of high-quality medical
care to veterans in Connecticut—
and to vets with complex cases
from across New England.
The majority of physicians
who work at the VA in West

R O B E R T L I S A K P H OTO

Haven have faculty appointments at Yale. “Our patients
get the latest advances in care
applied to their problems. They
get the depth and expertise of
a medical staff associated with
Yale, and they can get consultations with the top experts
at Yale and Yale New Haven
Hospital,” says Michael Ebert,
MD, the chief of staff at VA
Connecticut. At Yale, he is a professor of psychiatry and associate dean for veterans’ affairs.
Yale School of Medicine leaders say the association provides
Yale medical students, residents,
and fellows with valuable handson training. Plus, the VA’s a
fertile environment for conducting medical research. “Yale’s
longstanding relationship with
the VA is a win-win. It’s been
mutually beneficial for the medical students, residents, and fellows who train there; the faculty
who conduct research there;
and the veterans who receive
exceptional care,” says Robert J.
Alpern, MD, dean of Yale School
of Medicine and Ensign Professor
of Medicine (Nephrology).
These days, the Veterans
Health Administration is under
attack from critics who want to
replace it with private health
care. However, leaders at VA
Connecticut and Yale say the VA
system provides outstanding
lifelong care in most cases to a
patient population whose medical issues tend to be complex
and whose physical ailments
are often compounded by mental health problems. “The VA is

a unique national system that
offers a seamless web of services
from primary care to specialized
services to hospital to geriatric
and nursing care. When done
correctly, it’s a national model for
providing health care,” says John
Booss, MD, professor emeritus at
Yale School of Medicine, formerly
the national program director for
the VA’s neurology service.
When Theodis Fenn Sr.
returned from Vietnam as a
combat infantryman in 1967, he
suffered from malaria, hepatitis,
anxiety, and burns on his feet
from a base camp accident—and
had been exposed to Agent
Orange, the toxic defoliant. His
initial encounters with the VA
were disappointing. “They never
addressed my problems,” he says.
But eventually Fenn obtained
Daniel Federman, MD, a professor of medicine at Yale, as his
primary care physician, and
things turned around. Fenn has
received treatment for PTSD, lung
and prostate cancer, diabetes,
high blood pressure, and chronic
abdominal pain. “Dr. Federman is
my lifesaver. Without him, I’d be
dead,” says Fenn.
Leaders at Yale and the VA say
veterans like Fenn who have complex health problems benefit from
the expertise in diagnosis and
treatment that medical school
faculty can offer. For instance,
Yale and the VA Connecticut
Healthcare System helped define
and establish PTSD as a diagnosis
back in 1980, and today researchers at the VA are developing innovative treatments for it.

In return for their dedication
to better health care for veterans, Yale faculty physicians and
students who practice at the VA
get tremendous satisfaction from
treating veterans, who are typically grateful and willing to volunteer for studies that might help
their comrades. A number of Yale
faculty members treat patients at
the VA without compensation.
Some veterans become like
family to the med students and
residents. Uyen To, MD, assistant professor of medicine and
a Yale transplant hepatology
fellow who did her residency
at Yale as well, says she became
particularly close to one elderly
man—even telling him about her
wedding plans. At one point he
was near death. He grabbed her
hand and vowed, “I’m not going
to die before you get married.”
He pulled through.
For Yale’s medical students,
residents and fellows, the West
Haven hospital provides an excellent place to learn and practice
in a hands-on environment. In a
typical year, more than 200 medical students complete clinical
rotations there in a wide range
of medical specialties, working
closely with attending physicians
who also provide classroom training. At any given time, 15 percent
of the more than 1,100 residents
and fellows are on rotations at the
VA—during which time the VA
covers their salaries.
“The patients want to help
them learn. They have incredibly interesting medical histories and social histories around
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A safer way to live with
guns: residents and
doctors at Yale learned
first-responder techniques this fall, in order
to spread knowledge
to parents and children
who might be exposed
to shootings. If legislation limiting access
to firearms is not
forthcoming, everyone
needs to know first aid.
For more on the classes,
visit ymm.yale.edu/safe
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their military time, so it’s a
rich learning experience,” says
Seonaid Hay, MD, assistant professor of medicine and associate
program director of the Yale
Traditional Internal Medicine
Residency Program at the VA.
Yale faculty members teaching at the West Haven VA have
introduced a number of innovations there. One is the Center
of Excellence in Primary Care
Education, in which faculty
members teach residents how to
provide primary care through
interprofessional teams. At the
VA Connecticut clinics, residents
work with teams that include
nurses, medical assistants,
psychologists, pharmacists,
and others to provide care for
patients tailored to individual
needs. The program started in
a few clinics and now includes
most of the clinics at the West
Haven facility.
The VA provides tremendous
research opportunities for students, junior faculty members,
and senior faculty alike. The
VA is a fertile environment for
research partly because of its
size and scope. Researchers can
study large groups of patients at
VA medical centers around the
country. Because the VA was a
pioneer in electronic medical
records in the 1970s, much of its
historic data is easily accessible.
“Another attraction is the
patients. They’re willing to
participate in research because
they want to help their buddies.
There’s an altruistic drive,” says
Fred Wright, MD, the director
of research at VA Connecticut
and a professor of medicine

(nephrology) and of cellular and
molecular physiology at Yale.
The VA Connecticut Healthcare
System has 25 labs in West Haven,
with more than 500 active
research projects funded to the
tune of $45 million in grants and
run by 80 principal investigators
—all from Yale. Those labs are
currently conducting more than
50 clinical trials.
The program includes several
high-performing organizations.
The Center for Neuroscience and
Regeneration Research, headed
by Stephen Waxman, MD, PhD,
Bridget M. Flaherty Professor
of Neurology, discovers ways
to restore function in the nervous system after injuries and
strokes. The VA-Yale Clinical
Neurosciences PTSD Research
Program, headed by John
Krystal, MD, Robert L. McNeil,
Jr. Professor of Translational
Research and professor of psychiatry, and of neuroscience,
seeks biological approaches to
the treatment of trauma-related
disorders. And the NIH-DoD-VA
Pain Management Collaboratory
Coordinating Center, run by
Robert Kerns, PhD, professor of
psychology, of neurology, and of
psychiatry; Cynthia Brandt, MD,
MPH, professor of emergency
medicine and of anesthesiology; and Peter Peduzzi, PhD,
professor of biostatistics, helps
guide clinical trials of nondrug
approaches to pain management.
Yale faculty members who
serve at the VA are dedicated to
making life better for today’s
veterans by providing the best

care available, and to improving
care for generations to come via
research and teaching. Every
faculty member interviewed for
this story said they chose the
VA because it’s so gratifying to
help veterans.
Veterans interviewed returned
the warm feelings. Vietnam
vet Bill Broumas shunned the
VA after he returned from the
war. He received private insurance through his employer. But a
few years ago he decided to give
the VA another chance—partly
because of the Yale connection.
Now he’s a fan. “Every single person I meet there—they’re totally
interested in me,” he says. “They
all treat me like a human being.”
—Steve Hamm

»

Ten years of music
from Yale Medical
Symphony Orchestra
The Yale Medical Symphony
Orchestra (YMSO) kicked off
its 10th year with a concert in
Harkness Auditorium that was
filled to the rafters. “We love
looking out and seeing a packed
auditorium,” said symphony
conductor Robert Smith to the
crowd, which used every seat
and included people lining the
walls of the auditorium. “Eight
years ago, we had only about a
third of the auditorium filled.”
Now a group of more than
50 musicians from the School
of Medicine and Yale community perform composers like
Tchaikovsky and Brahms to a

R O B E R T L I S A K P H OTO

full house. Lynn Tanoue, MD,
professor of medicine (pulmonary), the group’s founder,
started the orchestra after
speaking with a school friend
who, like Tanoue, is a musician.
“We wouldn’t be here without
Dr. Tanoue,” said Smith, as she
was presented with flowers after
the anniversary performance.
Tanoue soon discovered that
medical school orchestras are
rare, but she found a supporter
in Thomas Duffy, MD, professor emeritus of medicine, then
the director of the School of
Medicine’s Medical Humanities
and the Arts Council. Duffy
agreed to provide initial funding, and Tanoue reached out to
the medical school community,
seeking musicians who might be
interested in playing together.
Tanoue said 200 people
responded, and she scheduled an
open rehearsal where everyone
would sight-read music together.
Tanoue asked Adrian Slywotzky,
director of instrumental music at
the Hopkins School in New Haven
at the time, to conduct the group.
“That first night, all these
people start showing up. It was
unbelievable,” Tanoue said.
“Adrian shows up with his arms
full of music. [On the top] is
Beethoven’s Fifth. I said, ‘Adrian,
you don’t understand. We’re doctors.’ He said, ‘No, no, it’s okay.’”
That night, Tanoue sat in the
Harkness balcony to listen to
the newly assembled group play
a piece by Rossini. They rose to
Slywotzky’s challenge, she said.
“Wow,” she remembers thinking.

“We could totally do this.” And
the group was off and running:
50 people from across the School
of Medicine made the commitment to rehearse and eventually
perform as an orchestra.
The symphony began regular
weekly rehearsals in February
2008, and at its first concert, performed Beethoven’s
Symphony No. 1. Two years later,
Robert Smith, who had taken
over Slywotzky’s position at
the Hopkins School, joined the
orchestra as conductor. Since
those early days, the symphony
has steadily moved on to more
challenging works. At the May
concert, the orchestra debuted
its first Tchaikovsky symphony,
No. 5, a piece, said Smith, that
goes beyond the capacity of
most similar orchestras. “They
work so hard every week, even
though they have pagers and
are constantly attending their
patients,” said Smith.
YMSO plays two concerts a
year: one in spring and another
in winter. There are often special concerts at Halloween.

Costumes, jack-o-lanterns,
and a glow-in-the-dark conductor’s baton accompany
an underscore set to creepy
Halloween poetry readings. The
2013 Halloween concert was a
breakthrough moment for the
group. “It opened everyone’s
eyes that we were a real orchestra,” said Smith. “We’ve been
packing the auditorium ever
since.” To celebrate their 10th
anniversary, Smith said, another
Halloween concert is planned
for October 27, with the winter
concert on December 7.
The participating musicians
come from all parts of Yale
School of Medicine. In addition
to faculty members and physicians, the players include volunteers, students, and staff from
many departments across the
school as well as from Yale New
Haven Hospital and the schools
of Nursing and Public Health.

YMSO recruits musicians from the School
of Medicine and the
broader medical
community in New
Haven. They’re held
to a high standard.
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Calamity struck in
August, when over
40 New Haven residents were poisoned
on the Green by a
synthetic cannabinoid.
Doctors from Yale
helped organize the
response, while firstresponders treated
victims on the scene.
For more on the poisoning,
visit ymm.yale.edu/poison
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“Music is the great equalizer.
Your stand partner could be a
famous scientist, or they could
be a lab technician or a student,”
said Tanoue. “The hierarchy that
is so strong at the university and
certainly in medicine totally
disappears, so that nobody is
more important than anybody
else. No one is running that
team except the conductor. And
many of these people in their
everyday lives are in charge of
whatever they’re doing.”
“Medicine is all about relationships and listening—with patients,
with nurses, doctors, hospital
staff, office staff, family members
of patients,” said Anna Reisman,
MD, associate professor of medicine, director of the Program
for Humanities in Medicine,
and a symphony flutist. “You
get nowhere if you’re not good
at listening, which also means
you have to be able to adapt your
response depending on what’s
said and how it’s said. The same
thing happens in an orchestra.”
To Smith, it’s no coincidence
that people who spend their days
steeped in science are also talented
musicians. Much of the group performed through high school and
college, he said. Some were music
majors as undergraduates or principal chairs in their high school
orchestras. “The idea of grasping for perfection, that kind of
drive and work ethic serves both
populations. It’s part of a person’s
character to do these things at a
high level and work hard at it. And
in both, they are using their hands.
It’s a technical application.”

Aishwarya Singh, a 2014
graduate of Yale College and current second-year medical student, nearly went to Julliard to
pursue the violin but chose Yale
College instead. She shares the
first stand with Brian Rash, PhD,
the orchestra’s concertmaster and
an associate research scientist in
neuroscience. “Music is one of
those things when you are always
learning, and medicine is like that
too,” said Singh. “It’s not finite.
That’s why I think, for a lot of
people, both appeal to them. For
a busy clinician it’s nice to have
something that’s an escape.”
Players connect at weekly
rehearsals, in between concentrating on whatever piece they
are working on. Graduate students meet professors who might
share their clinical interests;
chamber music groups formed
of orchestra members perform
beyond the symphony. Smith
said that there is little attrition
from year to year, so the musicians have come to know each
other well and form a tight-knit
community. “We come in and
we have this joyful, hardworking
time together,” Tanoue said.
Going into its 11th year, the
symphony is looking ahead to
the future, and is seeking new
ways to become sustainable, so
that it can keep growing. As
admission to its concerts is free,
the symphony’s funding comes
from grants and donations from
its members. Money for the
various incidentals required by
a symphony, including equipment, music, and support for the

conductor wasn’t always easy
to come by, but that changed
recently. Thanks to an effort in
spring of 2018 led by longtime
music and YMSO fans Robert J.
Alpern, MD, dean and Ensign
Professor of Medicine and his
wife, Patricia Preisig, PhD, professor of medicine (nephrology),
a $100,000 endowment was created to pay the YMSO’s conductor a stipend.
Retaining a professional
musical visionary is a key component of the symphony’s longterm success, and guarantees
that Yale’s medical community
will continue to meet and connect outside professional settings. Alpern and Preisig’s
efforts to institutionalize the
conductor’s position will be a
significant piece of their legacy.
“The conductors, we couldn’t
function without them,”
Tanoue said. “And both Adrian
Slywotzky and Robert Smith
have been amazing.”
Funds also mean YMSO can
take on different projects like
lecture series tied to performances and concerts; the ability
to bring music to patients’ bedsides; and children’s concerts.
“The orchestra dreams big,” said
Tanoue. “Why not?”
Smith said the group is ready
to take on those big dreams.
Musically, “I feel like we are
where we need to be with the
orchestra,” Smith said. They are
ready to perform bigger, more
iconic pieces for bigger audiences. “Now the fun begins.”
—Jeanna Lucci-Canapari

a collection of recent
scientific findings

ANOTHER DOWNSIDE
TO DEPRESSION

If you think the depression of a spouse or
loved one is making life sadder, you may
be right. A recent study published in the
American Journal of Geriatric Psychiatry,
conducted by Yale researchers and their
colleagues in Pittsburgh and Ann Arbor
suggested a correlation between the two.

MEMORY IN MODULES
Yale researchers have uncovered fascinating clues into the nature of human memory based on its mechanisms. Modules of
cells can be triggered and recombined in
the hippocampus, according to George
Dragoi, MD, PhD, assistant professor of
psychiatry and of neuroscience and senior
author of the study published in Neuron
in August.

A REGAL HONEY
Royal jelly might be more than just a stimulant for bees to develop into royalty—it
may provide clues into how cancer grows
or how it dies. While research at Yale by
Daryl Klein, MD, PhD, assistant professor
of pharmacology, using jelly from China
hasn’t yielded anything tangible yet, it can
be spread on buttered wheat bread, but
we wouldn’t recommend it.

ALL THE BEST ONES
AREN’T TAKEN

Molly Crockett, PhD, assistant professor
of psychology, conducted a study with
some counterintuitive conclusions about
what we say versus what we prefer. Most
people prefer to date or marry individuals
who prioritize the good of their family and
friends over strangers, which isn’t exactly
altruistic. We want to feel good more
than we want to be good.

Autumn 2018

9

Go with your gut

The microbiome: helping keep bodies healthy
IN TH E 19 9 0 s, geneticists hoped that mapping the human genome would provide a
path to treating many seemingly incurable or poorly understood conditions; obesity, dementia, and cancer, to name a few. As understanding of genetics expanded and improved,
however, scientists came to see the genome as just a first step in understanding a vastly
more complex world of interactions within the body, one that extended to organisms that
were not traditionally considered native or essential to humans—the microbiome.
Research at Yale focuses on a wide swath of relationships between microbes and
humans, from the gut to DNA. According to the latest inquiries, the evolution of Homo
sapiens is not just a tale of vertebrate mutations, in which genetic variation leads to useful
adaptation, but a hyper-complex series of mutually beneficial arrangements between the
human body and the many organisms that call it home.
In some cases, researchers are still attempting to establish a correlation between a
given microbe and conditions in humans. This issue explores some of those possibilities in
articles about diabetes, cystic fibrosis, and multiple sclerosis. In other cases where a correlation has been established, such as with Clostridium difficile infections, the question is
not whether microbes play a role in human health, but the specific nature of that role.
One fact has become apparent in compiling this issue of Yale Medicine Magazine:
the old idea of the human body as a self-sufficient entity constantly fighting hostile microbes is obsolete. We are collections of organisms working together to survive.
At least on a cellular level, the concept of the heroic individual is not just anomalous—it is
absurd, unworkable. Each person is a miracle of cooperation and altruistic mutual interest,
a collective of creatures. Good health and evolutionary success are the products of
alliances, not ruthless selfish competition.
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A
sophisticated
system
How researchers at Yale are complicating
the picture of human health.
by steve hamm | robert lisak photograph

A long struggle with Clostridium
difficile left Jane Norgren weak
and emotionally despondent—
until she underwent a revolutionary new therapy. Cured of the
infection, she’s eager to share her
success story with others who
may be suffering.
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Jane Norgren was suffering terribly. A pernicious bacterium,
Clostridium difficile, had taken up residence in her colon
and refused to leave—no matter what antibiotics she took.
As a result, she had bouts of uncontrollable diarrhea on
and off for nearly four years. It was a miserable situation.
She always had to be near a bathroom. “I felt like I was
untouchable,” she says.
Then Norgren’s agony was over. That’s because she was
one of the first people in Connecticut to benefit from
fecal microbiota transplantation (FMT). Most of the
existing bacteria in her digestive tract were killed by a
heavy dose of antibiotics and replaced by healthy bacteria from a fecal donor (her daughter). “I have been
fine ever since,” she says.
The procedure was performed by Paul Feuerstadt,
MD, an assistant clinical professor of medicine at Yale
School of Medicine. He says that more than 95 percent
of the patients he has treated in this way through the
Gastroenterology Center of Connecticut have recovered.
FMT is the first treatment that has emerged from a
wave of research on the role of the microbiome in health.
For years, most medical researchers treated microbes as
a sideshow to the main event—the role of genetics in illness and medicine. Now, many are turning their attention to the impact on health of the trillions of bacteria,
fungi, and other tiny organisms that colonize human
digestive systems, lungs, nasal passages, skin, vaginas,
and many other body parts and surfaces.
“For medical science, this is our next frontier. The
better we understand our microbiome, the better we’ll
be able to potentially avoid diseases or treat them more
successfully,” says Feuerstadt.
Researchers believe that the microbiome plays a role
in a wide variety of human diseases and conditions,
including inflammatory bowel disease, irritable bowel
syndrome, Crohn’s disease, lupus, chronic fatigue syndrome, fibromyalgia, cardiovascular disease, cancer,
Parkinson’s, diabetes, cystic fibrosis, asthma, autism,
and some forms of mental illness.
At Yale School of Medicine, researchers from more
than a dozen academic departments are studying the

14

ymm.yale.edu

microbiome. Some focus on understanding the fundamental mechanisms whereby bacteria interact with each other
and with our bodies. Others develop tools for sequencing
and editing genes in bacteria. Still others are focusing on
the effects of the microbiome on specific diseases.
While these are early days, it’s already clear that
Yale researchers are playing a key role in the microbiome revolution. For instance, Loren Laine, MD, professor of medicine and interim chief of the Section of
Digestive Diseases, was instrumental in establishing
the American Gastroenterological Association’s Fecal
Microbiota Transplantation National Registry, which
helps researchers assess short- and long-term outcomes associated with FMT.
This wave of microbiome research has been gathering strength for about a decade. However, the history
of such research began in the 1860s when the French
chemist Louis Pasteur showed that microbes are present all around us and in our bodies, and that some are
responsible for diseases. Ever since, medical scientists
have been studying the microbiota in the environment,
animals, and humans so that physicians can better
combat infection. With the emergence of antibiotics in
the 1930s and 1940s, many believed that infectious diseases would swiftly be eliminated. Sadly, it didn’t happen. Now, resistance to antibiotics is a major concern.
Until a little over a decade ago, most research on the
microbiome focused on which microbes played a role
in causing infectious diseases, and how. Then came
the Human Genome Project (HGP), launched in 1990
and completed in 2003, which provided the foundation
of a better understanding of the genetic basis of such
diseases as cancer. It was discovered that genes alone
were often not sufficient to fully explain why complex

Brain
After screening over 1,000 non-antibiotic
drugs against 40 gut bacterial strains,
researchers found that several classes—particularly antipsychotics—prevented healthy
microbes from thriving. The findings suggest
that these drugs could influence neurological
diseases via microbial interactions. However,
the study’s in vitro design is a limiting factor.
Eyes
The pathogenesis of glaucoma, the most common cause of blindness worldwide, remains
unclear. Researchers know that high intraocular
pressure (IOP) and overactive immune T-cells
play key roles. A study earlier this year hints
that limiting bacterial strains in the ocular
microbiome might also be a factor. Mice with
fewer ocular microflora strains experienced
less IOP-related damage compared to those
with more.

Lungs
Microbial communities in our gut might
increase the likelihood of developing asthma.
Infants with higher levels of the fungi Candida
and Rhodotorula in their gut, detected
through stool samples, were more likely to
be diagnosed with asthma at age 4.

M AYA S Z ATA I I L LU S T R AT I O N

Pancreas
Intermittent fasting might help alleviate
vision loss, called diabetic retinopathy, in
diabetic mice. This phenomenon could be due
to restructured gut microbiota. Mice who
fasted on alternate days had an increase
in a chemical chaperone called tauroursodeoxycholic acid, which has been shown to
slow retinal degeneration.
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diseases occur or how therapies work. So researchers
began to look more deeply into the genetic makeup of
microbes and their interactions with each other and
with human cells—both negative and positive.
In an effort reminiscent of the HGP, the U.S.
National Institutes of Health in 2007 launched the
Human Microbiome Project. The goal was to fund
research and collect data about the genomes and
interactions of all the microorganisms in or on our

Yale faculty members say this complexity must be
overcome. The ability to sequence and map human
genomes has raised hopes that physicians will be able
to understand an individual’s body so well that they
can deliver truly personalized medicine—customdesigned therapies and treatments that will work especially well for that individual. Yet it’s becoming clear
that understanding human genes and cells won’t be
enough. “To truly understand the signals that regulate

		Martin Kriegel

“This may become personalized medicine.
		 We need to look at … human genes,
and at the microbiome in the patient’s gut
		 and tissues. Based on these analyses, we
should be able to decide on the best treatment
		 for a particular patient in the future.

bodies. Research funded by the project provides
today’s scientists with a trove of data upon which to
base their new inquiries.
One factor that makes this research so complex is
that no two people have the same microbiome. While
broad commonalities exist, each human has his or
her own stew of bacteria and other organisms. In
addition, while our personal microbiomes tend to be
relatively stable, they change with the introduction of
new organisms from the environment. So my microbes
interact with my body differently than yours do with
your body; and they interact differently today than
they did six months ago.
And consider this: There are 150 times more genes
in our microbiome than in our genome.
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the expression of both healthy and diseased genes, you
need to understand the microbiome. Precision medicine
will be fairly imprecise without this,” says Gary Desir,
MD, the Paul B. Beeson Professor of Medicine and chair
of Internal Medicine.
Scientists admit they are still at the beginning
stages of understanding the role of the microbiome in
health. “We aren’t yet at the point where we can look
at what is there in a microbiome and tell you much
about what it can do. It’s hard to identify a diseased
microbiome if you don’t know what a healthy one is,”
says Andrew Goodman, PhD, an associate professor of
microbial pathogenesis.
Goodman is determined to change that. His
lab on Yale West Campus focuses on deepening

understanding of how microbes in our digestive
systems, the so-called gut microbiome, interact
with each other and us. He and his colleagues have
seen situations in which one microbe species uses a
vitamin produced by another to survive in the gut;
and others in which microbes fight each other to
the death. On the microbe-to-host axis, the team is
learning how gut microbes could affect how particular individuals respond to particular drugs.
So far, most of this experimentation involves mice—
but not just any mice: germ-free mice. Only by using
mice with no bacteria present can researchers introduce
individual species or consortia of microbes and study the
effects of their absence or presence. Although Goodman
has a dedicated team of experts in these techniques, the
med school also has a central germ-free mouse facility
that all the scientists can access.
Another essential element of microbiome research is
the tools that are used to read and analyze the genetic
code within microbes and then to edit or even recode
their DNA so that they interact with each other and
our bodies in different ways.
Scientists employ the same tools for microbes that
are used for human genetics research. The CRISPR/Cas9
technology has democratized gene editing by enabling
scientists to cut and paste snippets of DNA code relatively easily. But researchers at Yale are some of the
leaders in developing new approaches that don’t involve
breaking the double strands of DNA and killing cells.
One effort is led by Farren Isaacs, PhD, an associate professor of molecular, cellular and developmental
biology. His lab produces and uses high-throughput
gene engineering technologies. With these tools, the
researchers can rewrite the genomes of human cells
and bacteria on a large scale—introducing scores of
precise edits without creating double-stranded breaks
in the strings of genes. His team developed a technique called eukaryotic multiplex genome engineering
(eMAGE) and used it to alter the genetic information
in yeast. The team members hope this technique will
be used eventually to alter disease-causing genes in
human cells and microbes.
Earlier this year, Isaacs’ lab pitched in on an effort
aimed at engineering communities of gut microbes
to help humans digest cellobiose, one of the most

abundant disaccharides present in vegetables, which
our digestive systems don’t have the means to metabolize. If efforts like this pay off, we will be able to harvest more energy from the food we eat.
Across the spectrum of Yale academic departments, researchers are using germ-free mice and gene
sequencing and editing tools to advance research on
the role of the microbiome in a wide variety of diseases and body functions. Laypeople tend to think that
bacteria in the digestive system stays put, but in fact,
microbes migrate via the blood to a host of other body
organs and systems, including the liver, the lymph
nodes, and even the brain. Much of the research focus
at Yale is on infectious diseases, the immune system,
and autoimmune diseases.
Martin Kriegel, MD, PhD, FW ’06, adjunct assistant
professor of immunobiology, and of medicine (rheumatology), has been focusing on Enterococcus gallinarum, a
bacterium that his team discovered can migrate from
the gut into the lymph nodes, liver, and spleen in predisposed hosts—thereby producing an autoimmune response.
Kriegel’s research team found that they could suppress the
response caused by E. gallinarum in mice with an antibiotic or vaccine. Research like this could help pharmaceutical companies produce antibiotics and vaccines that are
particularly good at attacking specific bacteria.
“This may become personalized medicine,” says
Kriegel. “We need to look at the host predisposition
such as the human genes, and at the microbiome in
the patient’s gut and tissues. Based on these analyses,
we should be able to decide on the best treatment for a
particular patient in the future.”
Other labs are focusing on prevention in addition
to cures. Li Wen, MD, PhD, FW ’97, associate professor of medicine (endocrinology), is looking into
the causes of type 1 and type 2 diabetes. Her team’s
research has shown that certain types of gut bacteria
cause intestinal inflammation, which in turn promotes the development of type 1 diabetes. At the same
time, the research shows that obesity and other factors associated with type 2 diabetes are more prevalent
in patients with low diversity in the gut microbiome.
Down the road, she believes, people with a genetic
predisposition to diabetes may be able to fend off the
disease by consuming customized probiotic cocktails.
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“I think prevention is most important,” she says.
“It’s the most effective and economical way to deal
with diabetes.”
While most of the research at Yale concerns the gut
microbiome, a handful of faculty members are focusing
on other body parts or systems. For instance, Barbara
Kazmierczak, MD, PhD, a professor of medicine and of
microbial pathogenesis, specializes in the lung microbiome—specifically the effects of bacteria on cystic fibrosis.

of Pittsburgh, University of Michigan, and New
York University.
Several Yale researchers say they’d like to see a
larger and more coordinated effort to foster and support microbiome research. Such an initiative might
make it easier for them to secure funding and develop
more multidisciplinary collaborations. Moreover, there
would likely be benefits from expanding the variety
of research done at Yale. Right now, most of the focus

		Shari Hoffman

“This makes me optimistic that
			 patients may one day receive better
care and have better overall well-being.

Much of the research being done at Yale, while
promising, is not expected to deliver new treatments
or drugs for many years. But some projects might be
closer to the marketplace. For instance, two professors—Noah Palm, PhD, assistant professor of immunobiology, and Richard Flavell, PhD, Sterling Professor of
Immunobiology—are co-founders of a startup company
Artizan Biosciences, aimed at identifying harmful
bacteria in the gut and targeting them for destruction.
One of their first targets: inflammatory bowel disease.
“We found that when we take a healthy microbiota and
add one microbe to the mixture, the mouse gets sick. On
the flip side, if you’re able to block the pathologic effects
of that bug or eliminate it entirely, the mouse does not
get sick,” says Palm. The next step is figuring out how to
attack the bad bug—with targeted antibiotics, small molecules, or perhaps even phages.
Elsewhere around the country, a number of medical schools are establishing major research initiatives focused on the microbiome. Among them are
Harvard, University of Chicago, Stanford, University
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is on experimental science and the gut microbiome.
They’d like to see more done in data analysis and in
other microbiomes.
Goodman, who on his own keeps a web page
(medicine.yale.edu/microbiomeresearch) tracking
microbiome research at Yale, says, “I’d like to see it
happen. There’s a such a great base of people here.
There’s a lot of opportunity for really exciting things
with more coordination and resources.”
Meanwhile, local people who suffer from diseases
related to the microbiome are cheering Yale researchers
on. One of them, Shari Hoffman of New Haven, says,
“This makes me optimistic that patients may one day
receive better care and have better overall well-being.”
/yale medicine magazine
Steve Hamm is a contributor to Yale Medicine Magazine.

Intestines
Young people who suffer from Crohn’s disease
(CD), a chronic inflammatory bowel disease,
have reduced levels of beneficial bacteria in their
intestines, according to an oft-cited 2014 study
published in Cell Host & Microbe. Researchers
sequenced the genome of microbes in tissue
samples taken from the large intestine and
from fecal samples of about 600 children and
adolescents. None of the patients had received
treatment—usually antibiotics—for CD just yet.
The researchers pointed to the likely further
harm that antibiotics might wreak on their gut.
Colon
Fecal microbiota transplantation (FMT), known
colloquially as a “poop pill,” is the only microbiomerelated therapy that has been studied extensively in clinical trials. It is an established effective
treatment for difficult-to-treat or recurrent
Clostridium difficile infections.

Muscles
Microbes in the gut that are often found in people with multiple sclerosis (MS) appear to change
how white blood cells interact with the body’s
cells—including neurons—by making them more
likely to attack, according to a study that used
mouse models. Another study found that when
researchers implanted gut bacteria from humans
with MS into mice, those animals were more likely
to develop the autoimmune disease.
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Knees
Gut microbes may influence the adaptive immune response, which goes awry in autoimmune diseases like rheumatoid arthritis (RA).
In a small 2016 study, RA patients appeared to
have decreased gut microbial diversity and large
numbers of Collinsella bacteria, according to a
DNA analysis of stool samples.
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Take a look up and down the supermarket aisles: probiotics, loaded with the “good bacteria” once relegated to
yogurt and a few other fermented foods such as kimchi
and pickles, have escaped the dairy cases. They appear
in packaged foods now, with cereals, snacks, and even
chocolate infused with these good bugs. Studies of the
microbiome have provided an unintended boost to the
market for probiotics, shedding light on their power and
revealing some potential for therapeutic use beyond an
occasional yogurt to boost digestion.
Though probiotics have become a multimilliondollar cottage industry, much of the science behind
them remains murky. “The idea certainly has scientific
merit,” says Ruslan Medzhitov, PhD, Sterling Professor
of Immunobiology and a Howard Hughes Medical Institute investigator whose lab studies the microbiome’s

mysterious
medicine
Research shows that probiotics
can treat some ailments,
but has not yet shown why.

impact on diet and inflammation. “But the vast majority of claims surrounding probiotics are based on very
loose connections and correlations. This is not to say
that the idea is wrong, just that we don’t know enough
about the biology of commensal bacteria to start using
them in this wholesale manner.”
Still, those correlations are strong enough that
probiotics are beginning a transition from general food
supplements to medically valid treatments for serious
diseases. Priti Kumar, PhD, associate professor of infectious diseases, is examining a role for probiotics in HIV
treatment. One question that has long frustrated HIV
researchers is why HIV patients on a successful regimen
of antiretroviral therapy (ART) exhibit signs of early
immunosenescence. Evidence, Kumar says, points to a
change in the composition of the gut microbiome. Could

by jeanna lucci-canapari

probiotics be used to halt or reverse the premature aging process? Recent studies have examined introducing
the bacterial genus Lactobacillus, which is commonly
found in yogurt and other over-the-counter probiotics, into the diet of HIV patients. “Just introducing this
single probiotic strain in the diet seems to really make
a marked improvement, in bringing the immune system
several steps toward normalcy,” Kumar says.
While a potential success, this novel therapy
also highlights a limitation of the use of probiotics as
therapy. To maintain their healthy status, HIV patients
must take ART for the rest of their lives. Probiotics
must be used in the same way, because most of these
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good bugs have not evolved to adhere to the gut, and

many of these next-generation probiotics by definition

they end up passing through the body very quickly.

must be genetically modified. Jason Crawford, PhD, the

This finding poses another interesting question: “If

Maxine F. Singer ’57 PhD Associate Professor of Chem-

something is good for us, then why didn’t we evolve to

istry and associate professor of microbial pathogenesis,

hold on to it?” asks Medzhitov. “We are holding on to

cites an example of a probiotic he is working on that has

trillions of bacteria. Why are we not holding on to oth-

the potential to prevent colorectal cancer. “The chal-

ers that are good for us?”
Evolution may provide the answer. A recent finding
revealed that some “bad” bacteria in the gut microbi-

lenges for this example are in the regulatory landscape,
not the science,” he says. “A neutralizing enzyme that
we discovered protects humans from a particular toxin,

ome can promote obesity, which can lead to such meta-

but it needs to be secreted outside the cell as opposed

bolic diseases as type 2 diabetes, while other so-called

to inside the cell. We need to change that single gene to

“good” bacteria are associated with lean individuals.
“One is good and one is bad,” says Medzhitov.
“However, what we define as good and bad can be different than what would have been considered good
and bad in our evolutionary ancestors.” This observation can explain why so-called “good bacteria” are not
stable in the human intestines. “From an evolutionary
perspective, there is nothing good about them. They

have a secretion signal. But we can’t easily do that with
the current regulatory landscape. As soon as we modify
that organism, then it’s a GMO. That is a huge current
barrier between research science and market potential.”
Over-the-counter probiotics are not regulated
by the Food and Drug Administration. Because other
next-generation probiotics will be labeled as GMOs,
“it’s a different story,” says Medzhitov. “There is an

make you lean,” says Medzhitov. “That’s good if you

assumption that if they are genetically modified, there

are in Hollywood, but not if you are a caveman that

is something unnatural about them, as if all of evolu-

can only eat every three days.” Because human genes

tion is not about genetic modification. Bugs exchange

have not had the time to adjust to the drastic changes

genes all the time, they are always being genetically

in modern life that have occurred only in the last few

modified. There is nothing unnatural about it.”

hundred years, including modern medicine, hygiene,

As with all other discoveries, these probiotics of the

and obesity-causing food abundance, they still operate

future “would suffer from a certain amount of suspi-

under the assumption that what are now considered

cion,” says Medzhitov. “But over time, science will win.”

bad bacteria are actually good, and vice versa.
Medzhitov predicts that in the next 10 to 15 years,

Jeanna Lucci-Canapari is a frequent contributor to Yale Medicine
Magazine.

probiotics will make the leap to synthetic biology,
which would incorporate engineering and gene modification in their design. “Once we know enough about
how bacteria in the gut adapt to their environment,
understanding what makes them stable or unstable in
the host, or what makes them good or bad, and apply
the tools of synthetic biology, which are increasingly
sophisticated, one could theoretically create ‘designer
probiotics,’ where we could introduce genes that encode specific proteins that would metabolize certain
toxins, for example,” he says.
This novel approach to probiotics would still have
to pass muster with public opinion. Just as there is
strong support for natural commercially available
probiotics at the moment, there is powerful opposition
to genetically modified organisms (GMOs) in food. Yet
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Infection
control

A dangerous hospital-acquired
infection, Clostridium difficile, is now
increasing in the community.
by carrie macmillan | robert lisak photographs

Marianne J. Davies, assistant
professor of nursing at Yale
School of Nursing, is familiar with
Clostridium difficile (C. diff).
She describes a healthy immune
system as “checks and balances”
and C. diff infections as opportunistic, occurring when alreadyweakened immune systems are
thrown out of balance from,
for example, prolonged antibiotic
treatment of a particular illness
or infection.
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In the messy world of the gastrointestinal tract, good and evil
can, at least temporarily, coexist. The gut is home to trillions
of bacteria, fungi, viruses, and parasites. Most are helpful
in obscure ways, assisting the body in carrying out its various
vital functions. But some types of bacteria, including Clostridium
difficile (C. diff), are nefarious and opportunistic.
In a perfect world, beneficial bugs in the microbiome
keep the bad ones in check. But when normal bacteria
are wiped out (most often by antibiotics or illness), C. diff
flourishes and can cause a brutal infection characterized
by violent, uncontrollable diarrhea. Sometimes, especially in frail, very sick patients, this infection leads to
serious complications, even death.
“If there is a window to overtake a healthy environment, C. diff will find it,” says Marianne J. Davies, DNP,
APRN, an assistant professor of nursing at Yale School of
Nursing. “The normal bacteria in your bowel maintain
metabolism, break down food, and help with digestion.
When you take antibiotics, you lower the normal flora
that keep other pathogens out of the body. It’s like routine checks and balances.”
C. diff is the most common health care-associated
infection in the United States, causing approximately
500,000 infections and 29,000 deaths in 2015, according
to the Centers for Disease Control and Prevention (CDC).
And recently, for reasons researchers don’t understand, C. diff infections acquired in the community
(versus hospitals, where the rate is actually decreasing)
have been on the rise.
“There are theories as to why this is happening. Are
we seeing more aggressive or resistant strains because
facilities have become more efficient and are discharging patients before C. diff has had an opportunity to
demonstrate itself?” Davies asks. “Typically, the onset
is after you’ve been on antibiotics for five to 10 days.”
Preventive initiatives, such as limiting the use of
antibiotics unless truly necessary, are imperative, Yale
experts say.
NATURE’S BOUNTY
Commonly found in the air, soil, and water, C. diff is a
bacterium that occurs naturally in the gut microbiome
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of about 5 percent of the population. But that doesn’t
make it benign.
“Healthy people with a hearty immune system
may have C. diff in their intestinal tract, and they coexist with it,” Davies says, noting, “But it’s not what
we call normal flora.”
For patients in a health care setting, recent antibiotic use is the leading risk factor for contracting a C. diff
infection. People on antibiotics are seven to 10 times more
likely to get C. diff while on the medications and during the month after, the CDC reports. Antibiotics, which
destroy and slow the growth of harmful germs, end up
killing the good bugs too, explains Laura K. Andrews,
PhD, APRN, an associate professor of nursing at Yale
School of Nursing. This blanket effect gives C. diff room
to multiply and crowd out any normal bugs that remain.
Once entrenched, C. diff releases toxins that
inflame the protective lining of the large intestine. This
causes C. diff colitis, which entails up to 30 watery
stools a day, along with abdominal pain and fever.
“A mild case might mean taking oral antibiotics at
home to treat it. For severe to life-threatening cases,
you end up in the ICU and can even go into shock with
multisystem organ failure,” Andrews says. “Patients
can become profoundly dehydrated in less than
24 hours. They are losing liters of fluid.”
Other high-risk factors for C. diff infection include
being over age 65 and/or taking immune-suppressing
medications. Adding further challenges, C. diff can
survive for months, is resistant to disinfectants, and can
spread after contact with any contaminated surface.
“When you walk through a hospital, you see Purell
and other alcohol-based sanitizers all over. These are
a good reminder to staff and visitors that handwashing is important. Which is great, but these products are
just an extra step. They will not kill C. diff spores. For

Awareness of the threat posed
by C. diff and similar infections
has led to changes in prescription
habits and that’s a good thing,
says Laura Kierol Andrews.

that, she explains “diligent handwashing with hot soapy
water is essential.” It takes bleach to kill the spores on
surfaces and the friction of handwashing to rid hands of
C. diff.
HAIR OF THE DOG
Fortunately, many infections respond to treatment
with antibiotics. Typically, it takes a 10-day course,
but some people may require more time or a course of
IV antibiotics in a hospital.
“If you are harboring bacteria in your bowel, there
is risk of recurring infection, so it’s important to follow the prescribed course of antibiotics. Discontinuing
antibiotics when symptoms decrease can contribute to
antibiotic resistance,” Davies says.
Serious or resistant C. diff infections may require
more aggressive strategies. In some cases, a fecal transplant procedure (transferring bacteria from a healthy
person’s colon) may be necessary. For instance, surgery
may be required to fix a perforated colon.
“Some strains are resistant to antibiotics, which is
why we caution people not to self-medicate with antibiotics just because you have them,” Davies says. “We,
as medical professionals, are making concerted efforts
to be good antibiotic stewards and not overprescribe,
to minimize resistance to any strain.”
Andrews agrees. “People get a cold and often go to
the doctor demanding antibiotics, but a cold is a virus
and antibiotics won’t work. Taking them unnecessarily is causing virulence and resistance in many classes
of microbes,” she says. “By doing this, you are going to
cause resistance five or 10 years down the line.”
Researchers believe a particularly virulent strain of
C. diff—NAP1—that emerged in 2000 was spawned by
antibiotic overuse. This strain accounts for about 30 percent of all C. diff cases. “It’s a big toxin producer. It can also
be antibiotic-resistant and tends to recur,” Andrews says.
Furthermore, there has been a slow rise of community cases, including those among people who don’t fit
the mold. “We are seeing it in a younger population,
in those who aren’t immune-suppressed,” Davies says.
“If a 19-year-old who is not on antibiotics or immunesuppressing medications comes into my office
with significant diarrhea, C. diff is still something
to think about.”

Yale School of Public Health is part of the Connecticut
Emerging Infections Program, a collaboration between
the Connecticut State Department of Public Health and
the CDC. Its C. difficile surveillance program monitors all cases in New Haven County and is one of 10 sites
throughout the United States monitoring C. diff infections in the population.
“One of the biggest trends we are looking at is from
2011 to 2017, when we saw the overall number of C. diff
cases, as well as the hospital-acquired cases, go down.
But the community-associated cases were going up,”
says Danyel Olson, MS, MPH, the program’s surveillance coordinator. That trend continued until about
2015, Olson says, when the rates stabilized.
“The decrease in hospital infections could be from
implementation of infection control practices, antibiotic stewardship, and new treatment guidelines,”
Olson says. “We are unsure why infections increased
in the community.”
Andrews, for one, is optimistic about the tide turning when it comes to the overuse of antibiotics. “I think
half the battle is recognizing that this is a problem,” she
says. “C. diff infection rates may get worse before they
get better, but I think it goes back to getting antibiotic
prescriptions under control.” /yale medicine magazine
Carrie MacMillan is a staff writer for Yale Medicine, the clinical practice of Yale School of Medicine.
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Hookworm, one of humankind’s oldest foes, dwells in
the ground, waiting quietly for its victims. This gapemouthed parasite gains entry from warm, moist soils
through bare feet; takes a trip through the lungs; and
settles in the intestine to suck blood, often causing
anemia, malnutrition, and stunted development. More
than 500 million people worldwide are thought to be
infected, mostly in Latin America, Africa, and Southeast Asia, and vaccination development and deworming solutions are underway.
But the hookworm and related parasitic worms,
called helminths, may also have something to offer
us. Infection can be protective in some circumstances,
and Yale researchers are finding that the creatures can
teach us how our immune systems self-regulate.
“These parasites have evolved over hundreds of

Costs and
benefits
Some parasites may be unlikely
allies with human health.

thousands of years with their mammalian host.
They understand each other extremely well,” says
Michael Cappello, MD, a professor of pediatrics, of
microbial pathogenesis, and of public health, who
studies how nutrition influences susceptibility to
worm infection, as well as the efficacy—or lack
thereof—of treatment.
The human-worm relationship may be an agreement of sorts, Cappello suggests. “ ‘We’ll allow you in
as long as you don’t cause too much disease and you
don’t overwhelm us,’ ” he says, adding, “I think that we
have evolved to harbor light worm infections.”
As evidence, Cappello explains that curing worm
infections may not necessarily make a child healthier:
“In some places, [mass deworming] has brought down

by jenny blair, md ’04

the intensity of worm infections. But it’s been less
clear that those reductions are actually associated
with improved health.”
The worm might protect children from some of the
worst effects of malaria. In 2007, Cappello studied anemia levels in Ghanaian children who were infected with
malaria, hookworm, both, or neither. Having either
one of the two infections rendered a child more likely
to be anemic compared to uninfected children. With
malaria, the anemia was especially severe. Paradoxically, though, having both infections at once does not
multiply that likelihood, the team found. In fact, having
both parasites resulted in less severe anemia than in
victims suffering from just malaria.
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“The combination of these two parasitic diseases is

lab has found that immune cells begin making massive

such that they actually in some ways kind of cancel each

amounts of a molecule called IL-4. That leads to the

other out—and it may be that light hookworm infection

creation of a molecule called protein S, which plugs

blunts the response to malaria that leads to anemia,”

into TAM receptors and starts a negative feedback

Cappello says. “This was a surprising finding. … but

loop that calms the immune system.

it does add some supporting evidence to the idea that
light worm infections may be beneficial.”
To be clear, that’s light infection. Moderate and

Piecing together interactions like this one may
shed light on the hygiene hypothesis—a way of explaining why, as sanitation improves and people are ex-

heavy infections seem to do more harm than good, so

posed to fewer microorganisms, their rates of allergy

it’s important to keep the worm under control. One

and autoimmune diseases go up. Researchers believe

major tool for doing this is mass drug administration,

the immune system has evolved to anticipate its para-

or deworming people en masse with a single dose of

sitic foes and even to rely on their tools for tamping

an antiparasitic drug like albendazole. But while this

down the immune system. When the parasite and its

approach has been shown to reduce the prevalence of

moderating influence are absent, we turn on ourselves.

worm infections in some parts of the world, it doesn’t
always work as expected.
In West Africa, for instance, Cappello’s team has

This is the idea behind helminth therapy, in which
worms are deliberately ingested to treat autoimmune and allergic diseases. Pig whipworm eggs have

found that mass drug administration has spotty efficacy.

been studied as a treatment for inflammatory bowel

“Some villages have a cure rate with albendazole

disease, for example. Unable to develop to adulthood

that is 75 percent, whereas a few miles away a village

in humans, the eggs nonetheless deliver molecular

showed a cure rate of zero,” Cappello says. The reasons

messages to the human immune system that seem

have to do with the child’s nutritional status, the tim-

to curtail its propensity to attack itself. Intentional

ing of treatment, and some worms’ genetic resistance

hookworm infections have also been investigated for

to the drug, he believes.

allergic rhinitis.

So current worm control strategies may need to
evolve, and Cappello wants to be ready. “Our lab and a

But Rothlin believes it may be safer to pinpoint
which molecules the worms use to talk to the immune

small number of other groups around the world are try-

system, then mimic that communication with drugs.

ing to develop tools so that resistance can be detected

This approach could replace potentially risky experi-

when it emerges,” he says.

ments with parasite infection—a practice “I would

Hookworms are also chemistry wizards of sorts,
manufacturing molecules that lead to profound effects
in their hosts. They pump out anti-clotting molecules,
for example, to keep their blood meals flowing (Cap-

argue … can be very dangerous,” Rothlin says.
“Microorganisms are very good at this,” she adds.
“For millions and millions of years, they have tried to usurp
the regulatory pathways that we have. We can now study

pello spent his early career purifying these molecules,

them, identify which molecules [they use, and] know

one of which made it to human drug trials).

more about the regulatory pathway itself. Microorgan-

Perhaps more importantly, the worms also send
molecular communications that regulate the immune
system and ward off a strong attack. Carla Rothlin,

isms are great tools to understand immunology.”
Jenny Blair, MD ’04, is a frequent contributor to Yale Medicine
Magazine.

PhD, is an associate professor of immunobiology and
of pharmacology, who studies the immune system’s
brakes—which molecules and pathways signal that it’s
time to slow or stop an immune attack. One such brake
is called the TAM receptor. The body can stimulate
that receptor itself, but parasites can do it too. During
an immune response to helminth infection, Rothlin’s
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From bench
to book
How research findings make their
way to the classroom.
by john curtis | robert lisak photographs

Yale School of Medicine’s Richard Belitsky, left, and Michael
Schwartz work with faculty to
shepherd the latest medical research from the pages of publications into the school’s curriculum.
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From bench to book

In a first-year course called “Attacks and Defenses,”
discussions of the microbiome make up part of the
17 immunology lectures.
One lecture covers “what the microbiome is known to
do in the health and disease setting, everything from
Alzheimer’s to autism to obesity to cancer. It’s a very
broad stroke—there aren’t enough lecture hours to
get into specific areas,” said Akiko Iwasaki, PhD, the
Waldemar Von Zedtwitz Professor of Immunobiology,
and Molecular, Cellular, and Developmental Biology, and
a Howard Hughes Medical Institute investigator. “There’s
so much discovery going on in the microbiome field. I
believe it’s going to have to be expanded every year.”
The new medical school curriculum, unveiled in
the fall of 2015, anticipated exactly this kind of scientific advance.
“No matter what we define as the content of the
curriculum, no matter what we decide to teach at any
given point in time, as we are planning and implementing the curriculum, knowledge is continually
changing,” said Richard Belitsky, MD, HS ’82, FW ’83,
deputy dean for education, the Harold W. Jockers
Associate Professor of Medical Education, and associate
professor of psychiatry.
With each advance, faculty and administrators
gauge the breakthrough’s importance and whether it’s
something medical students need to know. For each
new finding, faculty must figure out how and who to
teach it, and—there are only so many hours in the day—
find space in the curriculum. “People who are teaching
are always thinking about this,” Belitsky said. “We rely
on the expertise of our faculty to determine the key
things our students need to know. We ask them to do it
not independently of the curriculum, but coordinated
with the rest of the curriculum.”
Belitsky jokes that managing this constant pressure
on medical education explains the large bottle of Tums
on the desk of Michael L. Schwartz, PhD, associate
professor of neuroscience and associate dean for curriculum. It falls to Schwartz to work such discoveries
into the classroom. This integration happens in two
ways, Schwartz said, the first of which involves faculty keeping tabs on what’s happening in the various
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departments. “Things come in organically by virtue of
the fact that our faculty are world leaders in their fields,”
Schwartz said, adding that course directors meet
monthly, and faculty have an annual retreat for discussions of curriculum.
Then there is also structured process, as occurred
with the opioid epidemic. In response to a growing
national crisis, a task force was convened to examine
what was being done to prepare future doctors. This
review included assessing the curriculum, how well
the related material was being taught and learned, and
whether the curriculum had omitted any critically
important information.
The curriculum integrates basic and clinical science across the four-year continuum. Students begin
clinical training early in medical school and revisit
the basic sciences during clerkships, which requires
faculty coordination to avoid unintended repetition
and to place new material in a useful context. “We
have structures in place to continuously examine this,”
Belitsky said, “and it’s a constant balancing act.”
So far there has been no schoolwide effort to introduce the microbiome into the formal curriculum, but
it is happening in some courses. Cyrus Kapadia, MD,
FW ’78, professor emeritus of internal medicine, is
planning to introduce it in a first-year master course
on energy and metabolism. First, he wants to find out
what students are already learning about the microbiome. Then, he’ll tap into faculty experts. “We have
some people at Yale who are known nationally for their
work on the microbiome,” he said. “Not to use those
people is a crime.” Kapadia hopes to have a plan for the
course by December.
Kapadia pointed out that while there is enormous
interest in the microbiome today, interest in gut flora
among scientists began decades ago. One fascinating
study published in 1934 examined the bacterial population at different levels of the intestines of dogs and
monkeys. This work was done decades before Watson
and Crick’s paper in Nature on the structure of DNA,

The Yale School of Medicine curriculum is the product of an everevolving set of variables and inputs.
Keeping it relevant requires constant input and balanced perspectives. From left, Richard Belitsky;

and with access to only primitive microbiological techniques. It wasn’t until the 1960s that more advanced
microbiological methods enabled a quantitative assessment of the microbial flora at different sites in the intestines from duodenum to colon. Studies in the native
population and in Peace Corps volunteers in the 1960s at
such centers as the Christian Medical College in Vellore,
India, further established the link between gut flora and
small intestinal mucosal architecture.
The availability of DNA sequencing methods has
brought the field to a higher level. “The big thing now,”

Leigh Cromey, student services
officer and manager of integrated
curriculum; Michael DiGiovanna,
co-director of integrated course
curriculum; and Michael Schwartz
review the curriculum changes.

Kapadia said, “is that we are talking about the role of
the microbiome in diseases affecting the mind, its role
in diabetes and obesity, and its connections to cardiovascular disease and to cancer.” Just as the medical
curriculum is constantly changing, the hope among
faculty is that students will appreciate that medicine
requires lifelong learning. Kapadia reminds his preclinical students: “Your education won’t stop when you
get to the wards!” /yale medicine magazine
John Curtis is a frequent contributor to Yale Medicine Magazine.
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In multiple sclerosis (MS), the immune system attacks
the nervous system, causing nerve and brain damage. Yet
the problem might actually originate in another place entirely: the gut. Yale researchers are among those teasing
apart how MS and other autoimmune diseases may arise
as a result of complex interactions among genes; the
intestines’ ability to maintain a tight boundary between
its contents and the rest of the body; and the bacteria
that live there.
To begin with, genetic mutations in MS “lead to
changes in the interactions between the immune system and the microbiome in the gut,” says David A. Hafler, MD, the William S. and Lois Stiles Edgerly Professor
of Neurology and professor of immunobiology.
A renowned researcher responsible for a number of
seminal discoveries in MS, Hafler was first to describe

Good bugs
gone bad
Helpful in some places, bacteria
can cause conditions like MS
when they break through the
body’s barricades.

the immune cells that attack myelin in the nervous system. He has also identified MS-specific genetic variants—
most of them related to immune genes—and unraveled
signaling pathways that make potential targets for drug
treatment. In 2013, he and his colleagues published the
landmark discovery that sodium chloride can lead to
autoimmunity in MS. He is preparing papers for Science
and Cell that map out the disease’s genetic architecture,
a culmination of almost two decades’ work.
Hafler is among a group of scientists who are uncovering genetic clues linking MS to the gut. In 2011, he
co-authored a paper listing scores of culprit MS genes,
one called INAVA, whose products show up in the gut.
Researchers recently found that INAVA also plays a key
role in Crohn’s disease—a type of inflammatory bowel
disease (IBD) that often accompanies MS. In a March
2018 paper in Science, a team at the Broad Institute
of MIT and Harvard reported that the INAVA variant

by jenny blair, md ’04

seems to loosen the integrity of the intestinal barrier,
rendering it permeable to molecules that shouldn’t be
able to pass through.
That phenomenon is sometimes called “leaky gut.”
Findings like the Broad team’s hint at the importance
of the gut lining to autoimmune disease. The digestive
tract is lined by epithelial cells that are tightly connected to one another, forming a barrier between the food
being digested and the bloodstream. Abnormal permeability of that layer has been observed in people with
IBD, as well as in mice suffering from a version of MS.
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Though leaky gut has become a popular scapegoat
in complementary medicine circles for everything

Moreover, a microbiome “transplant” from MS
patients into mice can actually provoke MS-like symp-

from autism to acne, it likely constitutes a real link to

toms, according to two papers appearing last fall in

inflammation, says Noah Palm, PhD ’11, FW ’15, assis-

Proceedings of the National Academy of Sciences.

tant professor of immunobiology, who studies the links

The patients’ bacteria seem to alter immune T cells’

between autoimmune disease and the gut microbiome.

behavior in the mice, leading to a type of encephalitis

His lab explores how communities of gut bacteria may

similar to MS.

influence not only the immune system, but also neurodevelopmental disorders like autism.
“There’s a lot of suggestive evidence in the literature

Bacteria also seem to influence brain cells. Tryptophan is an essential amino acid found in protein-rich
foods like meat, oats, and peanuts. It is converted in

that at least some sort of barrier disruption co-occurs

the body into the neurotransmitter serotonin and the

with a lot of these [autoimmune] diseases,” Palm says.

sleep-related hormone melatonin. But in a March 2018

Leaky gut seems to arise in a number of ways. In
some cases, bacteria may drill down to the barrier and
loosen it directly, Palm says.
Chronic high blood sugar can also do it, accord-

paper in Nature, a multinational group of researchers
reported that molecules from bacteria that metabolize tryptophan were also controlling microglia cells in
the brain that can stimulate astrocytes to produce an

ing to a team led by former Yale postdoctoral associ-

MS-like disease in mice. Such bacterial influence, the

ate Eran Elinav, MD, PhD, now at Israel’s Weizmann

authors suggested, may help explain why problems

Institute of Science. Elinav’s group linked leaky gut to

with the gut microbiome can impair recovery from

obesity and to type 1 diabetes, an autoimmune disease,

spinal cord injury—and why certain other species seem

in a March 2018 paper in Science.

to help recovery instead.

When the gut’s barrier comes down, it can let in bad

“The most important questions are: What is the

actors. In genetically susceptible mice, certain bacte-

microbiome? And what metabolites is it making in

rial species can traverse the intestinal barrier; travel

relation to the genetic architecture of the individual?”

to the liver and lymph nodes; and trigger a lupus-like

Hafler says. “That’s what I think it comes down to.”

autoimmune disease, according to a group led by Martin
Kriegel, MD, PhD, FW ’06, adjunct assistant professor

Jenny Blair, MD ’04, is a frequent contributor to Yale Medicine
Magazine.

of immunobiology at the School of Medicine. The team
members, who found the same bacteria in liver biopsies
of human patients with lupus, also published their results
in a March 2018 issue of Science.
There’s strong evidence to suggest that bacteria
are central to what goes wrong in MS and other autoimmune diseases.
“One of the things that we’re doing very intensively is
looking at the microbiome in MS,” Hafler says. “We and
others have found that there are clearly abnormalities.”
For instance, MS patients have a lower-thannormal abundance of Lactobacillus species—the kind
found in yogurt—and a higher abundance of Ruminococcus, a group of bacteria that can break down resistant starches. Exactly how such differences translate
into disease is still unclear. But in mouse models of MS,
inflammatory cells involved with the disease have been
observed to be influenced by gut bacteria.
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Evolving
attitudes
How microbes are changing
received wisdom.

by jeanna lucci-canapari | robert lisak photographs

As researchers compile evidence
of microbiome-related afflictions, faculty like Noah Palm help
place discoveries in their proper
contexts. In many cases, in which
an effect has been measured, the
cause remains unidentified.
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Evolving attitudes

Just as the ancient Greeks centered their understanding of
the human body on its four humors, and later eras separately
proclaimed the heart, the brain, and even the genome as the
leading player, the microbiome is now taking center stage. This
superorganism, as it has come to be known, has become a
major force in the biomedical research marketplace, attracting
substantial financial investment and taking up more and more
column inches in publication space. It is also becoming equally
clear that this young field still has a long way to go before it truly
shifts the paradigm for understanding disease.
“There are a lot of microbiome evangelists out there
who would tell you this has changed our world; it’s
changed it already and will continue to change it,”
says Noah Palm, PhD ’11, FW ’15, assistant professor
of immunobiology. Palm heads the lab that seeks to
understand the mechanisms by which the microbiome
interacts with the human hosts’ immune system, with
the ultimate goal of using these interactions to combat
disease. However, “so much is still in question, at a basic
science level, that must be understood before research
addresses how the microbiome can be used in therapies.”
The impatience and an eagerness to take advantage
of the resources brought by hype surrounding the
microbiome, says Palm, means that there is pressure to
fulfill the great promise of the microbiome too hastily.
“You have one or two failures and everyone gives up on
the whole thing. That’s actually one of my major fears
in terms of the whole field of biotech. I do believe there
will be transformative, paradigm-shifting therapies
that target the microbiome. But it’s not going to
be next year.”
Rather than evangelism, Palm says a common view
at Yale is a more “conservative, data-driven kind of
perspective,” he says. More conservative scientists
say microbiome research must focus on establishing
cause-and-effect evidence that the microbiome impacts
disease on a molecular level, rather than just inferring
causality through observation. According to Eduardo
Groisman, PhD, the Waldemar Von Zedtwitz Professor
of Microbial Pathogenesis, it is very difficult to locate a
sure causal relationship between a microbe in the gut
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microbiota and a function in its host, but there are many
undeniable correlations. “The underlying assumption of
all these correlations, which is very intuitive, is that if
you have an abundance of a particular type of bacteria
from the microbiome, then that organism is responsible
for a particular behavior,” he says. Groisman studies
bacteria, such as the gut-symbiotic Bacteroides thetaiotaomicron, in an attempt to find the mechanism behind
how organisms know when and how to shut particular
genes on and off.
“To a lot of scientists in mature fields, it’s not causation until you have a level of molecular insight that
makes you comfortable with how it’s really working,
not just that it works,” says Palm. To them, causation
means more than a presence or absence of particular
microbes or groups of microbes in the gut that cause
disease, proof of their function, and how they exert
that function. The challenge of causation is further
confounded by the vast diversity in the microbiome,
which varies widely among both individuals and
populations. “If you compare it to understanding, say,
the function of human genes, it’s of an intractable
magnitude. There are 150 times more genes in your
microbiome than in your own genome,” says Palm. The
microbiome is also intensely sensitive and can change
within an individual even within a day.
Further, the expense of experimentation influences
the research. Because of this, “there is a temptation
to generate a lot of data,” says Groisman. “What these
correlations are providing is information. But one cannot equate information with knowledge.”

Working alongside
researchers like Richard
Flavell, Palm looks for
causal relationships
between bacteria and
health outcomes. Scientists have established
promising correlations,
but the mechanisms by
which bacteria contribute to a healthy immune
system remain elusive.

In the past 10 years, major strides have occurred in
moving from correlation to causation in microbiome
research, with investigators using animal models,
particularly gnotobiotic, or germ-free mice, for proof.
Palm’s postdoctoral work with Sterling Professor of
Immunobiology Richard Flavell, PhD, used immunoglobulin A to identify the bacteria in the microbiome
that affect irritable bowel disease (IBD). Using these
mice, who are born completely sterile, the team was
able to isolate and identify a particular microbe that
drives the disease. “To me that’s causation,” Palm says.
“This bug is causing this disease.”
Groisman points to the most established use of the
microbiome in therapy as an example: fecal material
transfer, an FDA-approved treatment for the stubborn
and potentially deadly Clostridium difficile infection, or C. diff. The science behind this therapy, which
has been shown to work in the vast majority of C. diff
cases and even save lives, is based on an observed correlation, not causal effect, says Groisman. It is a very
recent development, with the long-term effects still
unstudied. “How many of these correlations will hold
over time? We will see.”
When it comes to the microbiome, “there are still
massive gaps in our fundamental knowledge,” says

Palm. Despite these growing pains, the field is making
progress toward maturity, balancing the excitement
over the potential of the microbiome with rigorous
study. “I think we have at least the beginnings of this
tool set to do the correlation-to-causation transition,”
says Palm. The tool set includes increasing improved
DNA sequencing, as well as culturing techniques that
allow annotation of the vast number of microbes that
make up the microbiome. “The hope is that by leveraging cutting-edge tools and feeding the data we get into
computational pipelines, you start to take bigger bites
of the apple, even though the problem seems intractable at this time,” says Palm. With careful use of the
resources available, the hope is that all this information will eventually turn to true knowledge.
This young field is not just a flash in the pan. “The
microbiome is not going away,” says Palm. “Just like
neurobiology is not going away. Nobody is going to stop
studying the brain. Same thing with the microbiome.”
/yale medicine magazine
Jeanna Lucci-Canapari is a frequent contributor to Yale Medicine
Magazine.
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“Consider the gut microbiome as the center of the
world,” says Li Wen, MD, PhD, FW ’97, associate professor of medicine (endocrinology). At the center of
a lined notepad, Wen draws a circle: this is the gut
microbiome. Radiating out, she draws arrows that
point to a wide span of human diseases, including
cancer, problems with the body’s circadian rhythm,
and autism. Among them are diabetes and obesity.
Yale researchers, including Wen, have been at the
center of pivotal studies that elucidate the gut microbiome’s connection to these disorders.
In a trial published in Nature way back in 2008, Wen
drew a line connecting the gut microbiome and type 1,
or juvenile, diabetes. Unlike type 2 diabetes, which is
largely driven by such environmental factors as diet,
type 1 is an autoimmune disease in which the body’s

An end to
dieting
Research on obesity may change
approaches to nutrition.

innate immune system does not properly function and
attacks its own insulin-producing beta cells. Using
genetically modified diabetic mice, Wen and a team
pinpointed a protein molecule, MyD88, that acted as a
“master controller” of innate immunity. The mice bred
without the MyD88 molecule in a pathogen-free environment did not develop type 1 diabetes. “We thought,
‘Wow, we’ve got a molecule with the potential to translate into clinical use in humans,’” recalls Wen.
As is often the case in research, Wen encountered
a complication: the mice, while diabetes-free, developed opportunistic bacterial infections. “We know
that when there is an infection, it affects the immune
system, so we needed to eliminate this possibility,” she
says. To do so, they performed the experiment with

by jeanna lucci-canapari

germ-free mice, which are bred to have no microorganisms of any kind living in or on them. Stunningly, the
diabetes returned.
“Science is like a dog chasing its own tail,” Wen
says. To understand this development, the team contaminated those germ-free mice with gut bacteria. The
diabetes rates in these mice dropped drastically. The
team concluded that a combination of genetics and
the commensal bacteria in the gut of the mice together
halted the development of type 1 diabetes, and this
combination would be critical in understanding how
autoimmune diseases develop.
“Genes alone do not explain these diseases.
Genetic shifts cannot occur as rapidly as immune
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diseases have been rising,” says Martin Kriegel, MD,

the specific microbe or set of microbes in the microbi-

PhD, FW ’06, adjunct assistant professor of immunobi-

ome that set off this reaction.

ology and of medicine (rheumatology).
Kriegel, in a study published earlier this year in
Science, discovered that gut bacteria in mice can break

The ultimate goal of finding these types of links,
says Wen, is to develop the ability to test for particular
microbes and use them as biomarkers, essential for

through the gut lining; travel to other organs; and

early prevention. The next step is to make the leap from

trigger an immune response, with implications for the

animal to human studies, which is fraught with chal-

treatment of lupus, another autoimmune disorder.
“Environmental factors also have to go through the so-

lenges. “I like to compare it to the human genome field
two decades ago, which was very exciting but also very

called barrier organs—the skin, the lungs, the gut—that

descriptive,” says Kriegel. “Now the field has matured.

are covered with microbes. The combination of genes,

A lot of insight is gained from animal studies, but these

environmental factors, and their influence on resident

studies are not always translatable to humans.”

microbes contributes to disease onset.”
Yale researchers have established a causal link be-

The ever-shifting constitution of the microbiome
is just one complication that frustrates inquiry. In their

tween the microbiome and obesity, which is a driver of

work, “we were struck by how quickly the microbiome

type 2 diabetes. Rachel Perry, PhD ’13, FW ’17, assistant

changes,” says Perry. “In rats, when we took food away

professor of medicine (endocrinology), discovered

for just 48 hours, there were drastic shifts in their

through a series of experiments that the mice with

acetate production, and, I suspect, in their microbial

high-fat diets produced high levels of acetate, a short-

composition. It took only two days of not having any-

chain fatty acid, which increases insulin secretion and

thing to eat for that to change very drastically. And the

raises the drive to eat. This acetate, says Perry, is de-

challenge in humans will be, how do we know we are

rived from the microbiome itself. The study, which she

sampling what we think we are sampling?” This is the

conducted with Gerald Shulman, MD, PhD, the George

nature of transformative science.

R. Cowgill Professor of Medicine (Endocrinology) and
co-director of the Yale Diabetes Research Center, was
published in Nature in 2016.
Much like Wen’s discovery, “we got into this

“The more one studies,” concurs Wen, “the more
questions one has.”
Jeanna Lucci-Canapari is a frequent contributor to Yale Medicine
Magazine.

largely by accident, as happens with a lot of interesting
science,” says Perry. When conducting experiments
that used acetate as a tracer, she and a team in Shulman’s lab noticed that obese animals were producing
higher levels of acetate. But they did not know where
in the body it was being produced, or why.
“Surprisingly to us, these obese mice had a large
increase in their plasma insulin concentration,” Perry
says. “Obese patients who are not yet diabetic have
very high plasma insulin concentrations, and that is
what is required to keep their blood sugars in the normal range. When we saw this increase in acetate, we
thought maybe these two things are related.”
The team discovered that acetate drives this
increased insulin secretion through activation of the
parasympathetic nervous system, leading the researchers to the gut microbiome as the source of that
acetate. Shulman and Perry are now looking to identify
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		 A heroic contribution
to medicine
Joseph Marshall Flint’s
genius for wartime surgery
Jacqueline Rocheleau
Because Joseph Marshall

complained: the doc-

surgery, Flint had condi-

did not usually have full-

Flint, MD, was trained

tor’s only former surgical

tions. He wanted labora-

time faculty or resources

as a research anatomist,

experience was during a

tories, classrooms, and

dedicated to research and
student training.

many at Yale did not see

sabbatical year in Germany

offices “in close contigu-

him as their top choice for

and Austria in 1906, right

ity with the hospital and

professor of surgery at the

before he arrived at Yale.

dispensary,” wrote Flint’s

however, a movement to

School of Medicine. When

Despite the controversy,

Yale colleague, Samuel

institute these changes in

the administration offered

Flint would prove his value

Clark Harvey, PhB 1907,

medical schools was begin-

Flint the position, other

to Yale during his 14-year

MD 1911. In the early 20th

ning. Flint joined the move-

faculty and physicians

career there, leading its

century, medical schools

mobile hospital unit in

ment and helped restore
Yale’s waning reputation as

World War I and reforming

a top medical school. For

surgical education.

example, to make up for

Before he accepted the
position as professor of
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Around this time,

the fact that medical students could not work with

patients, Flint instituted a

responsibility as com-

dog surgery course mod-

manding officer of Mobile

eled after the one Harvey

Hospital No. 39 at Aulnois-

Cushing, MD, had pio-

sous-Vertuzey, France, he

neered at Johns Hopkins.

used extraordinary skill

European conflicts

Flint was asked to head

and sound judgment in the

interrupted Flint’s prac-

the efforts to design and

organization and opera-

tice as a professor. During

implement a mobile hos-

tion of that unit, the first

the Greco-Bulgarian War

pital for American soldiers

of its kind in the American

in 1913, a precursor to

in France. Flint’s work

Expeditionary Forces.”

World War I, Flint served

with the French resumed

as a surgeon in an Athens

as he studied their mobile

commanding officer, Flint

hospital. Once World

hospitals to perfect the

contracted the Spanish

War I began, Flint started

American counterpart.

Flu and never fully recov-

volunteering on behalf

ered. Throughout the rest

of the French before the

Flint served as the com-

of his life he experienced

United States joined. He

manding officer of Mobile

persistent pulmonary

worked as a surgeon in a

Hospital Unit No. 39, the

problems. In Yale’s col-

French military hospital

Yale Unit, of the American

lection of his writings,

in 1915 and wrote papers

Expeditionary Forces. He

several books are filled

on military medicine. He

designed the Yale Unit for

also developed an X-ray

maximum efficiency, mod-

photography method to

eling it after both French

locate foreign bodies and

hospitals and Ford’s fac-

refined suspension meth-

tory assembly lines. If

ods used to treat fractures.

soldiers were the product

Flint took particular
interest in French military

factory workers, staying
in place to perform their

Flint told the Yale Daily

assigned duty as the belt

News, “Not the least inter-

rolled along to maximize

esting feature of military

hospital efficiency.

In fact, according to an

Grafe, PhD, the John R.
Bumstead Librarian for

article in the Yale Daily

Medical History and head
of the Medical Historical

with hand-drawn medi-

Yale to join the war and

Library, Flint’s design was

cal charts, colored pencils

provide a Yale Hospital for

efficient not only on paper

and red ink tracing the

wounded European sol-

but also in practice, low-

trajectory of his health.

diers as early as 1914.

ering the average operat-

Flint died in 1944, living

In 1917, a few weeks
war on imperial Germany,

BELOW A depiction of Flint’s
Mobile Hospital from a
scrapbook in the George
Milton Smith collection,
made by his brother, J. Andre
Smith, who served in WWI.

According to Melissa

News, Flint had pushed for

after the U.S. declared

LEFT Period publications
were positively effusive in
their praise for Flint’s hospital, which incorporated
the very latest in organizational theory.

along the assembly line,

months volunteering there,

of a military hospital.”

bile Hospital No. 39” was
based on experiences with
systems he had observed in
the French military, and during volunteer work with the
Greek alliance during the
Second Balkan War of 1913.

the staff members were the

hospital design. After five

surgery is the organization
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From 1917 to 1919,

During his service as

OPPOSITE PAGE Flint’s “Mo-

ing time per patient.
Because of the hospital’s success, Flint was

LEFT Overhead view of a
3-D architect’s model built
for presentation purposes.
The library still owns a copy
of the model, though it is
maintained only as a historical curiosity.

long enough to see Mobile
Hospital Unit No. 39 reinstituted in World War II.

awarded the Distinguished
Service Medal with a
citation that, according
to Harvey, read: “When
placed in a position of great
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Akiko Iwasaki
		 and the
Mighty Microbiome
iga ueno castle, also known as hakuho or
White Phoenix Castle, is considered one of the more
beautiful examples of an architectural style popular in
Japan during its early modern period. Located in Mie
Prefecture, Iga Ueno Castle was built to project political
legitimacy during great civil unrest. The castle provides
a visually striking reminder of a time in human history
when stability was just a couple of bad harvests from
breaking down, and a healthy country required tall,
thick stone walls to have a chance of surviving. Without
those great defensive bulwarks, feudal Japan’s fledgling
government might not have lasted to evolve into the
form that it holds today.
Perhaps it is fitting, then, that
a child of Iga should be among
the world’s foremost experts
on biological defense—specifically, conceptualizing how the
human body defends itself from
illness. Yale’s Akiko Iwasaki,
PhD, the Waldemar Von Zedtwitz
Professor of Immunobiology
and of molecular, cellular, and
developmental biology, and a
Howard Hughes Medical Institute
investigator, has dedicated her
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professional career to researching how the body perceives and
responds to certain infections.
As someone who helped
develop the field of antiviral immunology, Iwasaki
often focused her inquiries on
the microbiome. One recent

example involved medical trials
with mice raised in laboratories.
“We found a few years ago that
when you treat mice with antibiotics, and you get rid of most
of the microbiome, these mice
become susceptible to influenza,”
says Iwasaki. She explained
that the microbiome and the
mouse’s “natural” immune system work together to keep each
other healthy and prepared for
infection, and that when one is
compromised the entire system
falls apart. “It seems that the
microbiome is important for the
well-being of the immune system
in general,” Iwasaki says.
Scientists have known for
some time that animals with
germ-free guts are at higher risk
of disease and defect. Iwasaki
notes that these early observations from decades ago relied
on culturing bacteria from stool
samples with crude equipment, but that the technological advances of the last three
decades have spurred a kind of
categorical revolution in the field.
“With sequencing technology,
we can actually tell what type of
bacteria live in a particular gut,
even the ones one can’t culture
in a lab. We have the whole picture of what kinds of bacterial
species are present in a healthy
or unhealthy animal or, increasingly, person,” says Iwasaki.
One portion of this equation that isn’t understood yet is
the mechanical relationships
between body and microbe; which
causes produce which effects. In
part this difficulty is due to the
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sophistication of the microbiome.
Another difficulty, according to
Iwasaki, arises because the microbiome itself is far more complicated than is easily imaginable.
“Going past the microbiome,
and the human genome, you
have the metagenome, which
includes all the phages or
viruses that live within the
bacteria, and other viruses that
live inside our cells. So, we must
consider the virome, too.”
Another recent discovery is
that the 90 percent of human

DNA previously considered “useless junk” seems to have purpose,
and may not be human DNA at
all. “Retroelements occupy almost
half of our genome,” says Iwasaki,
noting that this is “huge real
estate compared to our coding
sequence. And we have very little
idea what they’re doing, though
they seem much more vital than
originally envisioned.”
Iwasaki finds the question
of infection fascinating—why
under some circumstances
bacteria and viruses are able
to coexist with the body in
healthy numbers and may even
be critical to its healthy function; while under different circumstances an imbalance can

create conditions for discomfort
or even death. Many recent
scientific advances have been
accompanied by an exponential expansion in the number
and complexity of questions
for laboratories.
After the period of civil
unrest ended in Japan, White
Phoenix Castle deteriorated and
was allowed to fall into ruin.
Later, though, it was rebuilt for
its architectural beauty and historical significance. One might
debate its utility as a defensive

Akiko Iwasaki, center, is
excited about the many
recent technological
and scientific advances
that have helped break
open the floodgates
for insights into
infection. Women’s
Health Research at Yale
undergraduate fellows
Haleigh Larson, left, and
Rose Davis look on.
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online exclusive

Patricia Nez-Henderson,
the first Native American woman to graduate
from Yale School of
Medicine, spoke with
Peter Salovey as part of
the President’s Women
of Yale Series. She
discussed issues like
identity, displacement,
addiction, and the
power of perseverance.
For more on their talk,
visit ymm.yale.edu/talk

structure necessary to the survival of Japan’s government, but
it and castles like it are significant in ways their builders may
not have imagined. As it turns
out, the health or illness of a
system can be immensely complicated, not just on a microscopic level but on a national
level as well.
—Adrian Bonenberger

»

From the killing
fields to the halls
of power

When Yale Medicine Magazine
last checked in with SreyRam
Kuy, MD, MHS ’09, FW ’09, it was
in the aftermath of Hurricane
Harvey last summer. Kuy, associate chief of staff at the Michael E.
DeBakey Veterans Affairs Medical
Center in Houston, was running the hospital’s emergency
response. She spent days on end
making sure the hospital took
care of its patients and staff, even
taking a turn working the cafeteria’s chow line.
Kuy has served the VA for
nearly two decades, in roles
spanning from Deputy Under
Secretary for Health, overseeing
a $14.5 billion-dollar budget, to
operating on colon cancers and
gangrenous limbs as a general
surgeon. “In any capacity, it is
an honor to serve these heroes,”
Kuy said.
She’s also been named one
of 10 recipients of the Women of
Worth award by L’Oréal Paris and
is a Daily Point of Light—the latest
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in a roster of awards that includes
the Ford Family Foundation’s
Gerald E. Bruce Community
Service Award and the American
College of Surgeons’ the Dr. Mary
Edwards Walker Inspiring
Women in Surgery Award. A
common thread is her service
to such vulnerable and underserved populations as veterans
and mothers on Medicaid. Given
her life story, said Kuy, “paying it
forward” is nonnegotiable.
“I am a child survivor of
genocide,” she said. “To be able
to live in America is a privilege I
am very grateful for. I owe it to
the generosity of strangers who
saw value in helping me when
I had nothing of value to give
back and there was no reason to
believe in me.”
Kuy was born in Cambodia in
1978. This was three years after
the Khmer Rouge took power
and emptied the capital, Phnom
Penh, at gunpoint. Kuy’s father
had a government job and her
mother was a school teacher. The
Khmer Rouge executed everyone
with an education, Kuy’s parents
feigned illiteracy. With her older
sister, they marched hundreds
of miles to forced labor camps in
the jungle. Kuy was born in one of
those camps.
The family saw a chance to
escape in 1979, when Vietnam
invaded Cambodia. They walked
by night and hid during the day
until they reached a refugee
camp in Thailand. Safety still
eluded them, however. A rocketpropelled grenade landed on
their tent, injuring Kuy and her

mother. A Red Cross surgeon
saved their lives.
Three refugee camps later, the
family landed in the Philippines,
where a Christian missionary
helped them enter the United
States as refugees. They settled
in Corvallis, Ore., in 1981. Kuy’s
father worked as a janitor at
Oregon State University and her
mother was a housekeeper at
Good Samaritan Hospital.
“My mom used to mop the
floors of the operating room
and now I work as a surgeon;
my dad mopped the floors at
Oregon State University, and
that’s where I graduated,” Kuy
said. “That is how amazing
America is.”
After college and medical
school in Oregon, Kuy completed her surgery residency at
the University of Texas Health
Science Center at San Antonio
and then applied to the Robert
Wood Johnson Clinical Scholars
Program that brought her to Yale.
“My journey as a health care
public servant has been as a direct
result of the skills I gained at Yale,”
she said. Biostatistics, public
health, computer programming,
and working with large data sets
were important, she said, but she
also learned “the courage to take
on challenges.”
In 2017, as chief medical officer for Medicaid in the state of
Louisiana, Kuy’s challenge was
the opioid crisis. That year she
was selected to the Presidential
Leadership Scholars Program, a
partnership among the presidential centers of Lyndon B. Johnson,
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George H.W. Bush, Bill Clinton,
and George W. Bush that brings
together mid-career leaders from
diverse backgrounds.
The fellows met once a month
for four-day workshops led by
former presidents, cabinet secretaries, and other policy luminaries. Kuy sought ideas on the
opioid crisis from her mentors
and colleagues, and came away
from each meeting with ideas that
she brought back to Louisiana.

“I walk into the classroom and
Kuy’s accolades extend beyond
there’s a judge, a lawyer, a teacher, medicine and health policy. She is
a poet, a Marine, a nurse—each
an accomplished writer with artioffering a perspective on how to
cles published in the Los Angeles
mobilize stakeholders,” she said.
Times and the Washington Post.
“I would come back from the class
Her novel, The Heart of a Tiger, is
just energized.”
based on her family’s experiences
Kuy organized town halls;
in the killing fields.
held symposiums; and ran
“My life is a miracle,” she said.
seminars for doctors, patients,
“It is a testament to the grace
and stakeholders. Her soluof God and the extraordinary
tions included payment reform
human capacity for compassion.”
to reduce overprescription of
—John Curtis
opioids and increasing accessibility to naloxone, used to treat
overdoses. “We reduced opioid
prescriptions among new users
by 40 percent,” Kuy said.

A child survivor of genocide, SreyRam Kuy has
followed an extraordinary path into medicine.
In Houston, she helped
organize responses to
the flooding brought by
Hurricane Harvey.
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question and answer

			 The immune system
& acts of kindness
DAVID G. SCHATZ, PHD,

chair of Yale School of Medicine’s

driving trend for growing
awareness has been a recognition that the immune
system is involved—often
quite directly—in almost
every human disease.

immunobiology department, can explain mind-bendingly

That’s particularly true

complex processes of the human body’s immune system in

for what we call the “dis-

relatable terms. For instance, here is his description of a pro-

like obesity, diabetes, and

cess that produces antibodies to fight viruses and bacteria as

heart disease. There’s also

follows: “This immune system reaction treats the chromo-

the process of inflamma-

some like a big long string. It comes in with molecular scissors, cuts the string, and then different enzymes come in
and tie the string back together in a new configuration.”
What Schatz just described is
called the variable, diversity,
and joining, or V(D)J recombination process, and it allows
T cells and B cells to randomly
assemble different gene segments. As a graduate student
at MIT in the lab of David
Baltimore, a virologist who
shared the 1975 Nobel Prize in
Physiology or Medicine, Schatz
established an assay to detect
V(D)J recombination activity. Then, in collaboration with
another doctoral student, he
used this assay to isolate and
discover two key enzymes in
this process called RAG1 and
RAG2. That groundbreaking
contribution to the field happened almost 30 years ago.
Schatz never slowed his pace.

{ To nominate a subject for Q&A, contact

Earlier this year, Schatz,
the Waldemar Von Zedtwitz
Professor of Immunobiology and
professor of molecular biophysics
and biochemistry, was elected to
the National Academy of Sciences
in recognition of his biochemical insights into RAG function
and evolutionary origins. He was
also a Howard Hughes Medical
Institute investigator between
1991 and 2017; has been elected to
the American Academy of Arts
and Sciences; and is a fellow of
the American Association for the
Advancement of Science.
Yale Medicine Magazine
caught up with Schatz, who
earned his BS and MS degrees in
molecular biophysics and biochemistry from Yale University
in 1980, to learn more about
the intricate processes of the
immune system and what he
values most in colleagues.

Yale Medicine Magazine, 1 Church Street, Suite 300, New Haven, CT 06510, or email ymm@yale.edu

46 ymm.yale.edu

Has public awareness
about the immune system and immunology
changed during your
career? Yes. The central

eases of modern society,”

growing recognition of
tion and the role it plays
in initiating or exacerbating diseases. Another
major trend in awareness
is within cancer immunology. Immunotherapy
has revolutionized our
thinking about cancer
and how it can be treated.

How would you summarize your research
focus now? I’ve gotten
very interested in the
question of how recombination processes evolved.
They are so unusual that
it immediately raises the
questions: Where did they
come from? How did the
human body come to have
these processes? We think
we can trace the V(D)J
recombination process to
a piece of DNA known as
a transposon. This is an
autonomous, mobile piece

Q&A WITH

David
Schatz

CONDUCTED BY

professor, is studying how

Kathleen Raven

the microbiome affects
health and disease states
in an area that few people
think about, which is the
of DNA that encodes an

metabolites that bacteria

The brilliant ideas that

enzyme that’s able to bind

produce. These are small

drive science forward can

to an element, snip it out

organic molecules that

happen at any time from

of one location, float, and

bacteria either have on

any one, so you just need

place it into another one.

their surface or secrete.

to make people as free

We believe that’s how the

We know virtually noth-

as possible from stresses

immune system can make

ing about what these tens

and pressures. The other

hundreds of millions of

of thousands of chemicals

point I would like to

different antibodies. Our

tell our body, what they

convey is the excitement

antibody genes are broken

signal our body to do

that comes from learning

up into discontinuous bits

or to think. Noah is just

something or discovering

and fragments of DNA,

beginning to explore the

something no one else

and the enzyme comes

diversity of those chemi-

has ever known before.

along and allows those

cals and their effects.

I would love to pass on

What message do you
have for today’s future
scientists? Once, during

new discoveries.

fragments to join in new
configurations. So, we
owe our adaptive immune
system to this mobile DNA

that deep love of making

element that gave us the

a conversation with David

capacity to snip and cut

Baltimore, I asked him

and rearrange our DNA.

what made a great leader.

What comes to mind
when you think about
the microbiome and
immunology? The

“Generosity.” That suc-

microbiome has come

I would like to convey

His answer was one word.
cinctly captures much
of what I admire in the
great leaders I’ve known.

onto the stage with

the message that respect

incredible speed. Much

and a humble eagerness

like the immune system

to learn from one another

itself, which influences

are incredibly important

almost every process

parts of doing science and

in the body, the micro-

being a scientist. Acts of

biome—we are learn-

kindness, sharing, coop-

ing—affects so many

eration, collegiality—all

different processes. There

of these have an enor-

is incredibly sophisti-

mous impact on atmo-

cated intercommunica-

sphere, and ultimately,

tion going on between

the productivity of the

the immune system and

whole scientific endeavor.
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the microbiome. In our
own department, Noah
Palm, PhD, assistant
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book review

		 Improving college
students’ mental health
By Cathy Shufro
is also an associate professor

forced penetration. Un-

feel a twinge of anxiety

at the university’s College of

wanted sexual contact

Group therapy can help
young adults with social

when dropping off a child

Medicine and the mother of

affects one in four students

at college. Although par-

two recent college graduates.

who are transgender, queer,

anxiety disorder, and Morris

ents may worry most about

In The Campus Cure,

or nonconforming, and one

recommends The Shyness &

drinking and sexual assault,

Morris explains how to rec-

in 20 men. Morris reminds

Social Anxiety Workbook.

more subtle disturbances can

ognize trouble. For instance,

parents not to blame a child

also hinder college students,

she advises parents to look at

who is victimized.

according to campus psychi-

their children’s grades each

atrist Marcia Morris, MD ’89.

term; bad grades may signal

life may look appealing,

Recently, Morris has been

problems that a student has

Morris reports that many

to excel effortlessly while

Although college social

She has also noticed an
increase in extreme perfectionism. Some people call it
“duck syndrome”: appearing

seeing more students who

managed to hide. For a fam-

students feel lonely. One

madly paddling just below

feel extremely lonely or are

ily facing a crisis, Morris

study found that one in

the water line. “Parents

obsessed with perfection.

provides step-by-step guid-

four students had felt “very

should tell their child that

ance on how to proceed.

lonely” during the previ-

they might get a C or even an

Those are among the

ous two weeks. Feeling

F in a class, and help them

The Campus Cure: A Parent’s

unchecked drinking is com-

isolated increases the like-

recognize that sometimes we

Guide to Mental Health and

monplace in college. One

lihood of depression and

do fail at things,” says Morris.

Wellness for College Students.

recent study showed that a

suicide, whereas more robust

External factors may con-

Drawing on research and

third of students had binged

social support correlates

tribute to an obsession with

on 25 years as a psychiatrist

on alcohol during a two-week

with higher grades. Morris

success, including the pres-

at the University of Florida,

period. (Binging means four

points out that children who

sure to find a job with a salary

Morris also discusses suicidal

or more drinks in two hours

grew up on Snapchat and

sufficient to repay loans.

behavior, financial stress,

for a woman and five or more

Instagram have missed some

eating disorders, struggles

for a man.) When parents

chances to practice face-to-

with sexual identity, and

warn their children against

face interaction.

problems she addresses in

She confirms that

Although The Campus
Cure addresses distressing
problems, the book pro-

psychosis. “This is my way of

misusing drugs and alcohol,

She suggests that stu-

vides case studies and action

trying to help parents prevent

Morris advises them to focus

dents seek friends by joining

checklists that can help par-

some of these problems, or to

on health, not morality. She

clubs, cultural groups, and

ents and students weather

address things quickly,” says

notes that young people who

religious organizations. A

difficulties. Morris sympa-

Morris, the associate program

observe that their parents

student might arrive early

thizes with parents of college

director for psychiatry at the

moderate their drinking are

at class and then chat with

students: “I want to make

University of Florida’s Student

likely to do the same.

a classmate, join a study

sure that when parents read

group, or arrange to meet a

the book, there’s no sense

Health Care Center. Morris

{ Send notices of new books to

Sexual predation is also
widespread. By graduation

of guilt. Raising kids is very

day, one in 10 female stu-

challenging, and there’s not

dents will have experienced

one formula for it.”
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potential friend for lunch.

It’s a rare parent who doesn’t
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end note

The end
of an era
O N A B A L M Y M AY A F T E R N O O N,

longtime Yale School of Medicine personality, beloved mentor,

accomplished doctor, and dedicated physician Margaret “Peggy” Bia, MD, FW ’78, stepped away
from her official responsibilities. Surrounded by former patients, colleagues, friends, and wellwishers, like David Mulligan, MD, (with Bia, above). Bia was visibly moved as the group offered
heartfelt thanks to her advocacy and leadership.
“Dr. Bia changed my life,” said Marilyn E. McNee, a transplant recipient, when asked for her
reflections. “It’s been 13 years since my transplant, and she’s always a phone call away.”
Bia, a powerful advocate for increasing the number and roles of women in medicine, was also
instrumental in emphasizing the importance of follow-ups after surgical operations and transplants
to patient health. She leaves behind a more integrated and patient-focused system, one in which
discharge from a hospital is not the end of care, but rather a new beginning.
—Adrian Bonenberger
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